IUPHAR Review on muscarinic M1 and M4 receptors as drug treatment targets relevant to the molecular pathology of schizophrenia
Cobenfy, a co-formulation of xanomeline and trospium, is the first drug not acting on the dopaminergic system of the CNS approved for the treatment of schizophrenia by the FDA. Xanomeline is a muscarinic M1 and M4 receptor (CHRM1 and CHRM4) agonist whilst trospium is a peripherally active CHRM antag...
Salvato in:
| Autore principale: | |
|---|---|
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
Elsevier
2024-12-01
|
| Serie: | Pharmacological Research |
| Soggetti: | |
| Accesso online: | http://www.sciencedirect.com/science/article/pii/S1043661824004559 |
| Tags: |
Nessun Tag, puoi essere il primo ad aggiungerne!!
|